Lack of Effect of Adjuvant Chemotherapy on the Elimination of Single Dormant Tumor Cells in Bone Marrow of High-Risk Breast Cancer Patients
- 1 January 2000
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 18 (1), 80
- https://doi.org/10.1200/jco.2000.18.1.80
Abstract
PURPOSE: There is an urgent need for markers that can predict the efficacy of adjuvant chemotherapy in patients with solid tumors. This study was designed to evaluate whether monitoring of micrometastases in bone marrow can predict the response to systemic chemotherapy in breast cancer. PATIENTS AND METHODS: Bone marrow aspirates of 59 newly diagnosed breast cancer patients with either inflammatory (n = 23) or advanced (> four nodes involved) disease (n = 36) were examined immunocytochemically with the monoclonal anticytokeratin (CK) antibody A45-B/B3 (murine immunoglobulin G1; Micromet, Munich, Germany) before and after chemotherapy with taxanes and anthracyclines. RESULTS: Of 59 patients, 29 (49.2%) and 26 (44.1%) presented with CK-positive tumor cells in bone marrow before and after chemotherapy, respectively. After chemotherapy, less than half of the previously CK-positive patients (14 of 29 patients; 48.3%) had a CK-negative bone marrow finding, and 11 (36.7%) of 30 previously CK-negative patients were CK-positive. At a median follow-up of 19 months (range, 6 to 39 months), Kaplan-Meier analysis of 55 assessable patients revealed a significantly reduced overall survival (P = .011; log-rank test) if CK-positive cells were detected after chemotherapy. In multivariate analysis, the presence of CK-positive tumor cells in bone marrow after chemotherapy was an independent predictor for reduced overall survival (relative risk = 5.0; P = .016). CONCLUSION: The cytotoxic agents currently used for chemotherapy in high-risk breast cancer patients do not completely eliminate CK-positive tumor cells in bone marrow. The presence of these tumor cells after chemotherapy is associated with poor prognosis. Thus, bone marrow monitoring might help predict the response to systemic chemotherapy.Keywords
This publication has 27 references indexed in Scilit:
- Epitope Specificity of 30 Monoclonal Antibodies against Cytokeratin Antigens: The ISOBM TD5-1 WorkshopTumor Biology, 1998
- Micrometastatic Breast Cancer Cells in Bone Marrow at Primary Surgery: Prognostic Value in Comparison With Nodal StatusJNCI Journal of the National Cancer Institute, 1996
- Reduction of metastatic carcinoma cells in bone marrow by intravenously administered monoclonal antibody: Towards a novel surrogate test to monitor adjuvant therapies of solid tumoursEuropean Journal Of Cancer, 1995
- Tumour cell detection in the bone marrow of breast cancer patients at primary therapy: results of a 3-year median follow-upBritish Journal of Cancer, 1994
- Methodological Analysis of Immunocytochemical Screening for Disseminated Epithelial Tumor Cells in Bone MarrowJournal of Hematotherapy, 1994
- Differential Expression of Proliferation-Associated Molecules in Individual Micrometastatic Carcinoma CellsJNCI Journal of the National Cancer Institute, 1993
- Bone marrow micrometastases in primary breast cancer: Prognostic significance after 6 years' follow-upEuropean Journal of Cancer and Clinical Oncology, 1991
- Breast Cancer Therapy: Exercising All Our OptionsNew England Journal of Medicine, 1989
- Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes).Journal of Histochemistry & Cytochemistry, 1984
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958